• Publications
  • Influence
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.
Induction of HIV-1 broad neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development but has remained challenging partially due to unusual traits of bnAbs, including high somaticExpand
  • 85
  • 8
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
Plasma is a source of broadly neutralizing antibodies for recombinant antibodies with enhanced potency and breadth. Engineering HIV immunity For rapidly mutating viruses such as HIV, antibodies thatExpand
  • 54
  • 3
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
A synthetic glycopeptide mimics a key neutralizing epitope on the HIV-1 envelope and can be used to isolate HIV-1 broadly neutralizing antibodies. Guiding anti-glycan antibodies Although it typicallyExpand
  • 46
  • 3
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.
Antibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected individuals and can evolve to neutralization breadth. Autologous neutralizing antibodies (nAbs) againstExpand
  • 42
  • 3
Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion
ABSTRACT An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to the gp120 V1/V2 region correlated inversely with infection risk. The RV144 proteinExpand
  • 76
  • 2
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors
Significance A current key goal of HIV-1 vaccine development is to learn how to induce antibodies that will neutralize many diverse HIV-1 strains. Current HIV-1 vaccines elicit strain-specificExpand
  • 55
  • 2
Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines.
Critical to the search for an effective HIV-1 vaccine is the development of immunogens capable of inducing broadly neutralizing antibodies (BnAbs). A key first step in this process is to designExpand
  • 42
  • 2
Tenascin-C is an innate broad-spectrum, HIV-1–neutralizing protein in breast milk
Significance Achieving an AIDS-free generation will require elimination of breast milk transmission of HIV-1, as breastfeeding is a cornerstone of infant survival in developing regions.Expand
  • 43
  • 2
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.
Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a goal of HIV-1 vaccine development. A bnAb target is the Env third variable loop (V3)-glycan site. ToExpand
  • 37
  • 2
Conformationally Selective RNA Aptamers Allosterically Modulate the β2-Adrenoceptor
G-protein-coupled receptor (GPCR) ligands function by stabilizing multiple, functionally distinct receptor conformations. This property underlies how “biased agonists” activate specific subsets of aExpand
  • 33
  • 2